美FDA禁止電子煙商Juul在美銷售尼古丁產品 思摩爾國際(06969.HK)續升5%曾創三個月高
美國食品及藥物管理局(FDA)禁止電子煙生產商Juul在美國銷售旗下尼古丁產品。
當局就公司提交的科學及公眾健康數據作出近兩年檢視後表示,公司須停止銷售及分發有關產品,並指有關申請欠缺足夠證據顯示產品對公眾健康合適。部分結果引發當局關注,因數據不足及自相矛盾,包括電子煙的子彈會否滲出有害化學物質。
Juul回應表示,不同意當局的決定,有意尋求在規管及法例下的所有選項,包括上訴及與監管當局接觸。
有望搶佔Juul美國市場份額的思摩爾國際(06969.HK)承接上日升勢,今早(24日)高開2.8%報22.25元後,初段曾升6.9%高見23.15元續創逾三個月高,隨後高位整固,現升4.9%,報22.7元,成交1,259萬股,涉2.87億元。
據悉,4月27日,美國FDA授予NJOY旗下NJOYAce換彈設備及三款煙草味補充裝允許銷售令,NJOYAce成為FDA批准通過的第一款陶瓷芯產品。思摩爾作為NJOY的產品核心供應商,或將直接受益於PMTA申請帶來的市場加快整合。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.